JP2008517900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517900A5 JP2008517900A5 JP2007537422A JP2007537422A JP2008517900A5 JP 2008517900 A5 JP2008517900 A5 JP 2008517900A5 JP 2007537422 A JP2007537422 A JP 2007537422A JP 2007537422 A JP2007537422 A JP 2007537422A JP 2008517900 A5 JP2008517900 A5 JP 2008517900A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- agent
- isd
- seq
- staphylococcus aureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62192104P | 2004-10-25 | 2004-10-25 | |
| PCT/IB2005/004126 WO2006059247A2 (en) | 2004-10-25 | 2005-10-25 | VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008517900A JP2008517900A (ja) | 2008-05-29 |
| JP2008517900A5 true JP2008517900A5 (enExample) | 2008-12-18 |
Family
ID=36565416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007537422A Pending JP2008517900A (ja) | 2004-10-25 | 2005-10-25 | スタフィロコッカス−アウレウスＩｓｄたんぱく質ベースの抗感染薬 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1812066A4 (enExample) |
| JP (1) | JP2008517900A (enExample) |
| KR (1) | KR20070085457A (enExample) |
| AU (1) | AU2005310981A1 (enExample) |
| CA (1) | CA2581746A1 (enExample) |
| WO (1) | WO2006059247A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597997A (en) | 2005-02-14 | 2013-10-25 | Epitopix Llc | Antibody compositions that bind polypeptides from staphylococcus aureus |
| AU2007281934B2 (en) * | 2006-01-18 | 2012-11-15 | University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| NZ570805A (en) | 2006-03-30 | 2011-10-28 | Glaxosmithkline Biolog Sa | Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus |
| CA2667788A1 (en) * | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
| KR20100072228A (ko) | 2007-08-31 | 2010-06-30 | 유니버시티 오브 시카고 | 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물 |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| US8758765B2 (en) | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| NZ614557A (en) * | 2009-03-23 | 2015-03-27 | Epitopix Llc | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use |
| HRP20160274T1 (hr) | 2009-04-03 | 2016-04-08 | University Of Chicago | Pripravci i metode vezane za varijante proteina a (spa) |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| AU2011274367B2 (en) | 2010-07-02 | 2015-04-23 | The University Of Chicago | Compositions and methods related to protein A (SpA) variants |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| WO2014144423A2 (en) * | 2013-03-15 | 2014-09-18 | Techulon Inc. | Antisense molecules for treatment of staphylococcus aureus infection |
| US9834768B2 (en) | 2014-12-31 | 2017-12-05 | Korea Advanced Institute Of Science And Technology | Effective method for specific gene silencing using artificial small RNA |
| CA3139981A1 (en) | 2019-05-14 | 2020-11-19 | The University Of Chicago | Methods and compositions comprising staphylococcus protein a (spa) variants |
| US12528882B2 (en) | 2019-09-13 | 2026-01-20 | The University Of Chicago | Methods and compositions for treating staphylococcal infections |
| CN120943954B (zh) * | 2025-10-20 | 2026-02-06 | 重庆原伦生物科技有限公司 | 抗金黄色葡萄球菌IsdB抗体的制备及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002306849A1 (en) * | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| EP2339344A1 (en) * | 2001-06-15 | 2011-06-29 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
| EP1412379B1 (en) * | 2001-08-02 | 2012-01-25 | The University Of Sheffield | Vaccine |
| NZ544542A (en) * | 2003-07-24 | 2009-01-31 | Merck & Co Inc | Polypeptides for inducing a protective immune response against staphylococcus aureus |
| ES2730275T3 (es) * | 2004-09-22 | 2019-11-11 | Glaxosmithkline Biologicals Sa | Composición inmunógena para uso en vacunación contra estafilococos |
-
2005
- 2005-10-25 WO PCT/IB2005/004126 patent/WO2006059247A2/en not_active Ceased
- 2005-10-25 JP JP2007537422A patent/JP2008517900A/ja active Pending
- 2005-10-25 AU AU2005310981A patent/AU2005310981A1/en not_active Abandoned
- 2005-10-25 CA CA002581746A patent/CA2581746A1/en not_active Abandoned
- 2005-10-25 EP EP05850805A patent/EP1812066A4/en not_active Withdrawn
- 2005-10-25 KR KR1020077011878A patent/KR20070085457A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2983695B1 (en) | Methods, uses and compositions of tie2 agonists | |
| JP2008536483A5 (enExample) | ||
| JP2008546390A5 (enExample) | ||
| JP2012092117A (ja) | Ｉｌ−２３活性を調節する方法；関連する試薬 | |
| JP2006519605A5 (enExample) | ||
| RU2012107993A (ru) | Полипептиды porhyromonas gingivalis | |
| JP2012522010A5 (enExample) | ||
| JP2010530238A5 (enExample) | ||
| JP2015522264A5 (enExample) | ||
| AU2019205602A1 (en) | Peptides having protease activity for use in the treatment or prevention of coronavirus infection | |
| JP2009545526A5 (enExample) | ||
| US20240218059A1 (en) | TGF-Beta 1 INHIBITORS FOR PREVENTING AND TREATING SARS-COV-2 | |
| WO2015131076A1 (en) | Nlrp6 inflammasome intestinal epithelium mucus secretion | |
| CA2693717A1 (en) | Immunology treatment for biofilms | |
| WO2022174768A1 (en) | Anti-viral peptides and compositions and methods of use thereof | |
| Lin et al. | Human cytomegalovirus and Epstein–Barr virus inhibit oral bacteria‐induced macrophage activation and phagocytosis | |
| JP2008517900A (ja) | スタフィロコッカス−アウレウスＩｓｄたんぱく質ベースの抗感染薬 | |
| WO2016079321A1 (en) | Antagonists of setdb2 for use in the therapy of infectious diseases | |
| JP2005534308A5 (enExample) | ||
| JP2016520570A (ja) | Ａ型インフルエンザウイルス感染の治療又は予防に使用するためのｐａｒ−４アンタゴニスト | |
| KR20010052244A (ko) | Ｎ-말단 콜린 결합 단백질 ａ 절단물의 아미노산을포함하는 폴리펩티드, 이로부터 유도된 백신 및 이의 용도 | |
| KR20110005710A (ko) | 변형된 Ｃｐｎ10 및 ＰＲＲ 시그널링 | |
| Zhao et al. | A broad-spectrum virus-and host-targeting antiviral peptide against SARS-CoV-2 and other respiratory viruses | |
| JP2008514196A5 (enExample) | ||
| JP2008512108A5 (enExample) |